Unknown

Dataset Information

0

Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action.


ABSTRACT: Nuclear factor-kappa B (NF-kappaB) is a transcription factor that plays a critical role across many cellular processes including embryonic and neuronal development, cell proliferation, apoptosis, and immune responses to infection and inflammation. Dysregulation of NF-kappaB signaling is associated with inflammatory diseases and certain cancers. Constitutive activation of NF-kappaB signaling has been found in some types of tumors including breast, colon, prostate, skin and lymphoid, hence therapeutic blockade of NF-kappaB signaling in cancer cells provides an attractive strategy for the development of anticancer drugs. To identify small molecule inhibitors of NF-kappaB signaling, we screened approximately 2800 clinically approved drugs and bioactive compounds from the NIH Chemical Genomics Center Pharmaceutical Collection (NPC) in a NF-kappaB mediated beta-lactamase reporter gene assay. Each compound was tested at fifteen different concentrations in a quantitative high throughput screening format. We identified nineteen drugs that inhibited NF-kappaB signaling, with potencies as low as 20 nM. Many of these drugs, including emetine, fluorosalan, sunitinib malate, bithionol, narasin, tribromsalan, and lestaurtinib, inhibited NF-kappaB signaling via inhibition of IkappaBalpha phosphorylation. Others, such as ectinascidin 743, chromomycin A3 and bortezomib utilized other mechanisms. Furthermore, many of these drugs induced caspase 3/7 activity and had an inhibitory effect on cervical cancer cell growth. Our results indicate that many currently approved pharmaceuticals have previously unappreciated effects on NF-kappaB signaling, which may contribute to anticancer therapeutic effects. Comprehensive profiling of approved drugs provides insight into their molecular mechanisms, thus providing a basis for drug repurposing.

SUBMITTER: Miller SC 

PROVIDER: S-EPMC2834878 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action.

Miller Susanne C SC   Huang Ruili R   Sakamuru Srilatha S   Shukla Sunita J SJ   Attene-Ramos Matias S MS   Shinn Paul P   Van Leer Danielle D   Leister William W   Austin Christopher P CP   Xia Menghang M  

Biochemical pharmacology 20100111 9


Nuclear factor-kappa B (NF-kappaB) is a transcription factor that plays a critical role across many cellular processes including embryonic and neuronal development, cell proliferation, apoptosis, and immune responses to infection and inflammation. Dysregulation of NF-kappaB signaling is associated with inflammatory diseases and certain cancers. Constitutive activation of NF-kappaB signaling has been found in some types of tumors including breast, colon, prostate, skin and lymphoid, hence therape  ...[more]

Similar Datasets

| S-EPMC2222661 | biostudies-literature
| S-EPMC2679404 | biostudies-literature
| S-EPMC2873166 | biostudies-literature
| S-EPMC2828279 | biostudies-literature
| S-EPMC544018 | biostudies-literature
| S-EPMC2624576 | biostudies-literature
| S-EPMC7605328 | biostudies-literature
| S-EPMC2519148 | biostudies-literature
| S-EPMC1544135 | biostudies-literature
| S-EPMC2782433 | biostudies-literature